Studies have discovered that IDH1 mutant glioma cells respond to medications that target enzymes in the de novo pyrimidine nucleotide synthesis pathway, providing new therapeutic options for patients with IDH mutations, which are common in gliomas (18). Here, IDH1 is linked to central nervous system cancer.